SCARA3 Antibody, FITC conjugated

1. CSR1 is SUMOylated at K582 and rapid ubiquitinated and degradated in prostate cancer cells. PMID: 29705808
2. demonstrated that CSR1 inhibited hepatocellular carcinoma cell proliferation, migration and invasion through inactivation of hematopoietic PBX interacting protein (HPIP) and its downstream PI3K/AKT signaling pathway. PMID: 28975986
3. Suppression of CSR1 expression is a novel mechanism critical for the oncogenic activity of miR-650. PMID: 25956032
4. Findings regarding the interaction of NADPH-P450 reductase (NPR) with cellular stress response (CSR) indicated function of NPR in hypoxic response. PMID: 24491563
5. Data indicate that the clinical samples showed an inverse correlation between SCARA3 gene expression, myeloma progression, and favorable clinical prognosis. PMID: 23537707
6. The binding of CSR1 with XIAP enhanced caspase-9 and caspase-3 protease activities. PMID: 22683311
7. The consistently high SCARA3 levels in both primary carcinomas and metastatic cells in effusions, and its up-regulation along disease progression from diagnosis to recurrence, suggest a role in ovarian cancer biology. PMID: 21855113
8. Results demonstrate the involvement of SCARA3 and SCARA5 in the uptake of PF14-oligonucleotide nanocomplexes. PMID: 22138034
9. Down-regulation of CSR1 protein expression by promoter methylation is associated with tumor growth and metastasis of prostate cancer PMID: 16436673
10. CSR1 appears to induce cell death through a novel mechanism by hijacking a critical RNA processing enzyme CPSF3. PMID: 18806823

显示更多

收起更多

HGNC: 19000

OMIM: 602728

KEGG: hsa:51435

STRING: 9606.ENSP00000301904

UniGene: Hs.128856